KORU Medical appoints Christopher Pazdan as COO, eliminates CTO role held by Brian Case

KORU Medical Systems, Inc.

Christopher Pazdan appointed Chief Operating Officer, effective July 18, 2024, from SVP Operations.
Brian Case's position as Chief Technology Officer eliminated, termination effective September 16, 2024.
Pazdan's base salary set at $350,000, annual bonus up to 50% of base salary; severance includes 12 months base salary plus health premiums.
Pazdan joined KORU in 2021, has over 20 years experience in medical technology QA/regulatory affairs.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brian Case

Chief Technology Officer

KRMD · KORU Medical Systems, Inc.

Effective: 2024-09-16
Filed: July 24, 2024, 7:59 PM ET

On July 18, 2024, the Company’s Board of Directors eliminated the position of Chief Technology Officer, currently held by Brian Case, effective as of September 16, 2024. Mr. Case’s employment with the Company will terminate concurrently with elimination of that position.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Brian Case was terminated as Chief Technology Officer at KORU Medical Systems, Inc..

Action: terminated
Role: Chief Technology Officer

Exact text from the filing

On July 18, 2024, the Company’s Board of Directors eliminated the position of Chief Technology Officer, currently held by Brian Case, effective as of September 16, 2024. Mr. Case’s employment with the Company will terminate concurrently with elimination of that position.

View on SEC.gov

KORU Medical Systems, Inc. filing history →

Source: SEC EDGAR

accession 0001161697-24-000314

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.